International Liver Congress

Meeting News

NAFLD simulator offers teaching tools, risk prediction

April 12, 2019
VIENNA — A new, open-access simulator gives providers the tools to show natural progression of non-alcoholic fatty liver disease to their…
Meeting News

Constipation drug Amitiza improves hepatic markers in NAFLD

April 12, 2019
VIENNA — Lubiprostone was tolerable and improved hepatic markers among patients with nonalcoholic fatty liver disease, according to data…
Meeting News

HCV vaccine using chimp adenovirus shows promise in healthy humans

April 12, 2019
VIENNA — Use of adenovirus derived from chimpanzees showed increased activity and sustainability of T cell activation in an early study of a…
Meeting News

Scale-up of MTCT intervention in Africa vital to HBV elimination

April 12, 2019
VIENNA — Epidemiological modelling showed that scale-up of hepatitis B mother-to-child transmission intervention and treatment in Africa will…
Meeting News

1 in 5 young adults show signs of fatty liver; 1 in 40 have fibrosis

April 12, 2019
VIENNA — Young adults around aged 24 years showed a high prevalence of nonalcoholic fatty liver disease, with progression increasing with age…
Meeting News

Mavyret for HCV effective despite psychiatric disorders, substance abuse

April 12, 2019
VIENNA — A real-world analysis of Mavyret for hepatitis C showed patients with key comorbidities such as psychiatric disorders and substance…
Meeting NewsVideo

VIDEO: Understanding resources crucial to reducing cirrhosis readmissions

April 11, 2019
VIENNA — In this exclusive video from the International Liver Congress 2019, Elliot B. Tapper, MD, from the University of Michigan, discusses…
Meeting News

‘Watershed moment:’ Ocaliva improves NASH in phase 3 trial

April 11, 2019
VIENNA — Despite missing one of the two primary endpoints set with the FDA, Ocaliva produced antifibrotic effects in a dose-dependent manner in…
Meeting News

GKT831 safely reduces hepatic markers of cholestatic disease, fibrosis

April 11, 2019
VIENNA — GKT831 achieved rapid dose- and time-dependent reductions in markers of cholestatic bile duct disease and liver injury in patients…
Meeting News

Fatty liver prevalence, mortality rising in HIV population

April 11, 2019
VIENNA — As HIV reaches new levels of control and hepatitis C virus treatments give cures, providers must be aware that non-alcoholic fatty…